
|Videos|May 26, 2017
Improving Radiotherapy Responses in Head and Neck Cancer With Galectin-1
Author(s)Dhanya K. Nambiar, PhD
Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5






































